&nbsp;

cancerplan6.pdf

Jan 2025

Regimen

CRBPPEME+AMIV

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

pemetrexed,

CARBOplatin,

amivantamab (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Jan 2025

Document

Systemic-Treatment-Implementation-Plan-2024-2028-EN.pdf

Jan 2025

Document

Systemic-Treatment-Implementation-Plan-2024-2028-FR

Jan 2025

Systemic Treatment Program Implementation Plan 2019–2023

Systemic Treatment Program

Document

Standardized-Adnexal-Masses-US-Reporting-Explanatory-Notes.pdf

Jan 2025

Drug

cetuximab

Other Name(s): Erbitux®

Quick Link(s): Drug Monograph, Patient Info Sheet

Aug 2023

Regimen

CISPFU+PEMB; FU+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CRBPFU+PEMB; FU+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CAPECISP+PEMB; CAPE+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

ODB - General Benefit

capecitabine

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2025

Regimen

CAPECRBP+PEMB; CAPE+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

Drugs Used: